** U.S.-listed shares of Israel-based drug developer PolyPid PYPD.O rise 28.1% to $4.17 premarket

** Co says its experimental treatment to prevent surgical site infection in patients undergoing abdominal colorectal surgery met main goal of late-stage trial

** Treatment called D-PLEX100 is administered along with standard of care treatment to provide prolonged anti-bacterial activity directly at surgical site to prevent infections

** Co says treatment showed 58% reduction in rate of surgical site infections in patients treated with D-PLEX100 vs standard of care

** Co expects to submit marketing application to U.S. FDA in early 2026

** Up to last close, stock up 7.6% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com))